Physician profile
Meghan Elizabeth Maccleary
NPI 1972921724
$86,506.66
in general payments reported to CMS, 2019-2025
18 companies · $85K in 2025
The $85K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $137 · 2021: $177 · 2022: $191 · 2023: $174 · 2024: $366 · 2025: $85K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $72K · Travel and Lodging: $11K · Food and Beverage: $2,822 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $72,000.00 |
| Travel and Lodging | $10,712.97 |
| Food and Beverage | $2,822.22 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $84,713.04 | 2024-2025 | Hemosphere |
| Applied Medical Resources Corporation | $469.75 | 2024-2025 | |
| Hologic Sales and Service, LLC | $363.47 | 2019-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Myosure Tissue Removal Device, Acessa Provu System |
| Abbvie INC. | $249.79 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $161.62 | 2023 | Myfembree |
| Therapeuticsmd, INC. | $131.89 | 2019 | |
| Astellas Pharma US INC | $89.99 | 2025 | |
| Covidien Lp | $68.61 | 2019 | |
| Merck Sharp & Dohme LLC | $48.54 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.25 | 2020-2023 | |
| Exeltis, USA INC. | $32.43 | 2020-2021 | |
| Mylan Pharmaceuticals INC. | $29.57 | 2021-2022 | |
| Daiichi Sankyo INC. | $24.75 | 2021 | |
| Agile Therapeutics, INC. | $18.13 | 2021 | |
| Coopersurgical, INC. | $16.40 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $15.62 | 2021 | |
| Millicent US INC | $14.65 | 2025 | Femring, Intrarosa |
| Avion Pharmaceuticals | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Maccleary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.